Obesity and chronic kidney disease: A current review.

IF 1.9 Q3 ENDOCRINOLOGY & METABOLISM
Saira Nawaz, Rajkumar Chinnadurai, Saif Al-Chalabi, Philip Evans, Philip A Kalra, Akheel A Syed, Smeeta Sinha
{"title":"Obesity and chronic kidney disease: A current review.","authors":"Saira Nawaz,&nbsp;Rajkumar Chinnadurai,&nbsp;Saif Al-Chalabi,&nbsp;Philip Evans,&nbsp;Philip A Kalra,&nbsp;Akheel A Syed,&nbsp;Smeeta Sinha","doi":"10.1002/osp4.629","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Obesity poses significant challenges to healthcare globally, particularly through its bi-directional relationship with co-morbid metabolic conditions such as type 2 diabetes and hypertension. There is also emerging evidence of an association between obesity and chronic kidney disease (CKD) which is less well characterized.</p><p><strong>Methods: </strong>A literature search of electronic libraries was conducted to identify and present a narrative review of the interplay between obesity and CKD.</p><p><strong>Findings: </strong>Obesity may predispose to CKD directly as it is linked to the histopathological finding of obesity-related glomerulopathy and indirectly through its widely recognized complications such as atherosclerosis, hypertension, and type 2 diabetes. The biochemical and endocrine products of adipose tissue contribute to pathophysiological processes such as inflammation, oxidative stress, endothelial dysfunction, and proteinuria. The prevention and management of obesity may prove critical in counteracting both the development and advancement of CKD. Moreover, measures of abdominal adiposity such as waist circumference, are generally associated with worse morbidity and mortality in individuals receiving maintenance hemodialysis.</p><p><strong>Conclusion: </strong>Obesity is a risk factor for the onset and progression of CKD and should be recognized as a potential target for a preventative public health approach to reduce CKD rates within the general population. Future research should focus on the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in patients with CKD and obesity due to their multi-faceted actions on major outcomes.</p>","PeriodicalId":19448,"journal":{"name":"Obesity Science & Practice","volume":"9 2","pages":"61-74"},"PeriodicalIF":1.9000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073820/pdf/","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Science & Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/osp4.629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 10

Abstract

Background: Obesity poses significant challenges to healthcare globally, particularly through its bi-directional relationship with co-morbid metabolic conditions such as type 2 diabetes and hypertension. There is also emerging evidence of an association between obesity and chronic kidney disease (CKD) which is less well characterized.

Methods: A literature search of electronic libraries was conducted to identify and present a narrative review of the interplay between obesity and CKD.

Findings: Obesity may predispose to CKD directly as it is linked to the histopathological finding of obesity-related glomerulopathy and indirectly through its widely recognized complications such as atherosclerosis, hypertension, and type 2 diabetes. The biochemical and endocrine products of adipose tissue contribute to pathophysiological processes such as inflammation, oxidative stress, endothelial dysfunction, and proteinuria. The prevention and management of obesity may prove critical in counteracting both the development and advancement of CKD. Moreover, measures of abdominal adiposity such as waist circumference, are generally associated with worse morbidity and mortality in individuals receiving maintenance hemodialysis.

Conclusion: Obesity is a risk factor for the onset and progression of CKD and should be recognized as a potential target for a preventative public health approach to reduce CKD rates within the general population. Future research should focus on the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in patients with CKD and obesity due to their multi-faceted actions on major outcomes.

Abstract Image

Abstract Image

肥胖和慢性肾脏疾病:最新综述
背景:肥胖对全球医疗保健构成了重大挑战,特别是通过其与2型糖尿病和高血压等共病代谢状况的双向关系。也有新的证据表明,肥胖和慢性肾脏疾病(CKD)之间存在关联,但这种关联不太明确。方法:对电子图书馆进行文献检索,以确定并呈现肥胖与CKD之间相互作用的叙述性综述。研究结果:肥胖可能直接导致CKD的发生,因为它与肥胖相关的肾小球病变的组织病理学发现有关,也可能间接导致其广泛认可的并发症,如动脉粥样硬化、高血压和2型糖尿病。脂肪组织的生化和内分泌产物有助于病理生理过程,如炎症、氧化应激、内皮功能障碍和蛋白尿。肥胖的预防和管理可能被证明是对抗CKD的发展和进展的关键。此外,腹部脂肪的测量,如腰围,通常与接受维持性血液透析的个体更严重的发病率和死亡率相关。结论:肥胖是CKD发病和进展的一个危险因素,应被视为降低普通人群CKD发病率的预防性公共卫生方法的潜在目标。由于胰高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白2抑制剂对主要结局的多方面作用,未来的研究应侧重于在CKD和肥胖患者中使用胰高血糖素样肽-1受体激动剂和钠-葡萄糖共转运蛋白2抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Obesity Science & Practice
Obesity Science & Practice ENDOCRINOLOGY & METABOLISM-
CiteScore
4.20
自引率
4.50%
发文量
73
审稿时长
29 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信